Clinical Trial Update: Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen

View source ↗

Summary

A clinical trial analysis comparing the risk of cardiovascular events in HIV-infected individuals treated with lopinavir/ritonavir–based HAART versus efavirenz-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Human Immunodeficiency Virus Infection
• Hypercholesterolemia

Drugs mentioned

• Kaletra (lopinavir)
• Sustiva (efavirenz)

Snippet

Sponsor: Helios Salud | Conditions: HIV, Hypercholesterolemia | Status: UNKNOWN